This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
by Zacks Equity Research
Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
Haemonetics (HAE) Q3 Earnings Top Estimates, 2024 View Raised
by Zacks Equity Research
Haemonetics' (HAE) proprietary technology, Persona, continues to gain momentum in the third quarter.
3 Medical Services Stocks to Buy Amid Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and HQY are set to gain the most. However, staffing shortages continue to disrupt the growth trend.
Molina Healthcare (MOH) Q4 Earnings Beat on Premium Growth
by Zacks Equity Research
Molina Healthcare (MOH) expects adjusted EPS to be at a minimum of $23.5 in 2024, which represents a year-over-year improvement of 12.5%.
DexCom (DXCM) Launches One+ Real-time CGM System in Europe
by Zacks Equity Research
DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
by Zacks Equity Research
Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.
Inspire Medical (INSP) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) U.S. region witnesses strong revenue growth in the fourth quarter.
Centene (CNC) Q4 Earnings Beat on Membership Growth, View Up
by Zacks Equity Research
Centene (CNC) expects adjusted EPS to be a minimum of $6.70 in 2024, higher than the 2023 figure of $6.68 per share.
Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT
by Zacks Equity Research
Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.
PacBio's (PACB) New Kits to Boost Its Revio Sequencing System
by Zacks Equity Research
PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.
ELV vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. AVTR: Which Stock Is the Better Value Option?
Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and McKesson (MCK) have performed compared to their sector so far this year.
BD (BDX) Q1 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.
Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.
HCA Healthcare's (HCA) Q4 Earnings Beat on Improved Admissions
by Zacks Equity Research
HCA Healthcare (HCA) expects EPS in the range of $19.70-$21.20 for 2024, the midpoint being 7.6% higher than the 2023 figure.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Elevance (ELV) Q4 Earnings Beat on Premium Growth, Dividend Hiked
by Zacks Equity Research
Elevance Health (ELV) expects 2024 premium revenues to remain in line with the 2023 level.
Elevance Health (ELV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 1.26% and 1.51%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Elevance Health (ELV) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Elevance Health (ELV) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.
ELV or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. HQY: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.